Monash IVF Group (MNIV.F) 주식 개요모나쉬 IVF 그룹은 호주와 말레이시아에서 보조 생식술 및 전문 여성 영상 서비스를 제공합니다. 자세히 보기MNIV.F 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장0/6과거 실적2/6재무 건전성2/6배당3/6강점공정 가치 추정치보다 낮은 72.6% 에서 거래올해부터 흑자전환위험 분석주식은 유동성이 매우 낮습니다향후 3년 동안 수익이 연평균 0.1% 감소할 것으로 예상됩니다.7.48% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.모든 위험 점검 보기MNIV.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.408.1% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7m307m2016201920222025202620282031Revenue AU$306.9mEarnings AU$28.2mAdvancedSet Fair ValueView all narrativesMonash IVF Group Limited 경쟁사AunaSymbol: NYSE:AUNAMarket cap: US$307.9mCommunity Health SystemsSymbol: NYSE:CYHMarket cap: US$373.9mJointSymbol: NasdaqCM:JYNTMarket cap: US$127.3mU.S. Physical TherapySymbol: NYSE:USPHMarket cap: US$976.6m가격 이력 및 성과Monash IVF Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가AU$0.4052주 최고가AU$0.7452주 최저가AU$0.40베타0.731개월 변동0%3개월 변동n/a1년 변동n/a3년 변동n/a5년 변동n/aIPO 이후 변동-45.95%최근 뉴스 및 업데이트공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.더 많은 업데이트 보기Recent updates공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.공시 • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australia공시 • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.공시 • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.주주 수익률MNIV.FUS HealthcareUS 시장7D0%0.5%1.8%1Yn/a14.5%28.4%전체 주주 수익률 보기수익률 대 산업: MNIV.F의 US Healthcare 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: MNIV.F의 US 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is MNIV.F's price volatile compared to industry and market?MNIV.F volatilityMNIV.F Average Weekly Movementn/aHealthcare Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.0%안정적인 주가: MNIV.F의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine MNIV.F의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트2014892Malik Jainudeenwww.monashivfgroup.com.au모나쉬 IVF 그룹은 호주와 말레이시아에서 보조 생식술 및 전문 여성 영상 서비스를 제공합니다. 이 회사는 진단 산부인과, 부인과 초음파 및 불임 치료 서비스를 제공합니다. 또한 3차 수준의 산전 진단 및 시험관 아기 치료 서비스도 제공합니다.더 보기Monash IVF Group Limited 기초 지표 요약Monash IVF Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?MNIV.F 기초 통계시가총액US$177.42m순이익 (TTM)US$16.38m매출 (TTM)US$178.15m10.8x주가수익비율(P/E)1.0x주가매출비율(P/S)MNIV.F는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표MNIV.F 손익계산서 (TTM)매출AU$271.92m매출원가AU$181.60m총이익AU$90.31m기타 비용AU$65.31m순이익AU$25.01m최근 보고된 실적Jun 30, 2025다음 실적 발표일해당 없음주당순이익(EPS)0.064총이익률33.21%순이익률9.20%부채/자본 비율39.5%MNIV.F의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당7.5%현재 배당 수익률41%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/09/06 19:50종가2025/06/10 00:00수익2025/06/30연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Monash IVF Group Limited는 14명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Martyn JacobsBell PotterBradley WatsonBell PotterTara SperanzaBell Potter11명의 분석가 더 보기
공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
공시 • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australia
공시 • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.
공시 • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.
